Press Release | Newsroom | Medtronic | Form 8.1 – Covidien

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Form 8.1 – Covidien

DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 13, 2014--

Covidien plc:

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

         
             
Name of person dealing (Note 1)           Covidien plc
Company dealt in           Covidien plc
Class of relevant security to which the dealings being disclosed relate (Note 2)           Ordinary Shares
Date of dealing           8 Oct 2014 and 23 Oct 2014
 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                     
          Long         Short
          Number   (%)         Number   (%)
(1) Relevant securities         N/A – Covidien plc only holds treasury shares          
(2) Derivatives (other than options)                    
(3) Options and agreements to purchase/sell                    
Total                    
               

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

                     
Class of relevant security:         Long         Short
          Number   (%)         Number   (%)
(1) Relevant securities                    

(2) Derivatives (other than options)

                   

(3) Options and agreements to purchase/sell

                   
Total                    
               

3. DEALINGS (Note 4)

(a) Purchases and sales

                     
Purchase/sale         Number of relevant securities         Price per unit (Note 5)
Purchase (Redemption to Treasury)         223

26

9

        US$88.08

US$89.98

US$89.17

               

(b) Derivatives transactions (other than options transactions)

                         
Product name,

e.g. CFD

      Nature of transaction

(Note 6)

      Number of relevant securities

(Note 7)

      Price per unit

(Note 5)

                         
                 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

                                                 
Product name,

e.g. call option

      Writing, selling, purchasing, varying etc.       Number of securities to which the option relates (Note 7)       Exercise price       Type, e.g. American, European etc.       Expiry date       Option money paid/received per unit (Note 5)
                                                 
                                   

(ii) Exercising

 
Product name,

e.g. call option

      Number of securities       Exercise price per unit (Note 5)
                 
           

(d) Other dealings (including transactions in respect of new securities) (Note 4)

                 
Nature of transaction

(Note 8)

      Details       Price per unit

(if applicable) (Note 5)

                 
           

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

None

 
 
 

Is a Supplemental Form 8 attached? (Note 9)

         

NO

Date of disclosure           13 November 2014
Contact name           Lisa Clemence
Telephone number           +1 508-452-4375
Name of offeree/offeror with which acting in concert            
Specify category and nature of acting in concert status            
         

A person interested in 1% or more of any relevant securities in the Covidien plc (the “Company”) may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. This requirement will continue until the offer period ends.

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Source: Covidien plc

Covidien
Peter Lucht, 508-452-4168
Vice President
External Communications
peter.lucht@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

X